Cartalax

Cartalax is the synthetic short peptide Ala-Glu-Asp, usually abbreviated AED, and it occupies the cartilage and connective-tissue slot in the Khavinson bioregulator catalogue. The commercial logic mirrors the rest of that catalogue: an organ-specific tissue extract came first (Sigumir, derived from cartilage), the active low-molecular-weight fraction was then characterised, and a defined synthetic peptide was released as the second-generation product. Cartalax is that second-generation molecule for joints.

The mechanistic claim made by the originating group at the Saint Petersburg Institute of Bioregulation and Gerontology is that peptides this small are not simply degraded to amino acids. They argue that AED and its relatives penetrate the cell and the nuclear envelope, interact with specific promoter sequences and histone proteins, and shift transcription in aged tissue back toward a more youthful expression profile. For cartilage, the predicted consequence is that resident chondrocytes and recruited mesenchymal stem cells resume producing structural matrix rather than degradative enzymes.

There is laboratory work consistent with that prediction. A 2023 review in the International Journal of Molecular Sciences collected experiments in which short peptides of this class pushed cultured human mesenchymal stem cells toward a chondrogenic phenotype, with increased expression of SOX9 and of the two matrix components that matter most in joint tissue: aggrecan, the large proteoglycan responsible for the water-binding compressive stiffness of cartilage, and type II collagen, the dominant fibrillar protein of the cartilage network [1]. A separate 2023 report from the same lineage described peptide exposure suppressing the senescence-associated secretory phenotype in chondrocyte cultures, which in practical terms means lower output of the inflammatory signals that drive cartilage breakdown [2]. A third 2023 paper looked specifically at replicative ageing in human mesenchymal stem cells and reported that peptide treatment preserved chondrogenic differentiation capacity across passages [3]. Broader gene-expression work on the same peptide family in ageing stem cell cultures has been published in Molecular Biology Reports [4].

Animal work in osteoarthritis and disc degeneration models is where the more commonly quoted claims originate: reductions in interleukin-1 beta and tumour necrosis factor alpha in joint tissue, and preserved proteoglycan content in the intervertebral disc. These endpoints are biologically coherent, because IL-1 beta and TNF-alpha are the canonical drivers of matrix metalloproteinase and aggrecanase activity in osteoarthritic cartilage, and proteoglycan loss is the earliest measurable change in disc degeneration. The problem is not the plausibility of the endpoints. The problem is provenance. Nearly all of it is published by, or closely connected to, the group that developed and commercialises the peptide, much of it in Russian-language gerontology journals with limited external peer review, and none of it has been reproduced by an independent laboratory outside that network.

What does not exist is any human evidence. There is no randomised controlled trial of Cartalax in osteoarthritis, in tendinopathy, in disc disease, or in any other musculoskeletal condition. There is no registered study on ClinicalTrials.gov. There are no published human pharmacokinetics, so the central mechanistic assumption, that an orally or parenterally administered tripeptide survives and reaches chondrocyte nuclei at a meaningful concentration, remains untested in people. That is why we place Cartalax at tier 4 rather than tier 3: the preclinical signal is real enough to be worth watching, but nothing bridges it to human outcomes.

Dosing in circulation is entirely vendor-derived. The standard protocol quoted by suppliers is 5 to 10 mg per day, delivered subcutaneously or intramuscularly, for a course of 10 to 20 consecutive days, repeated after an interval of four to six months. That cyclic pattern is characteristic of the whole Khavinson product line and reflects the group's theoretical position on transient transcriptional re-tuning rather than any dose-finding data.

On safety, the honest summary is that nothing alarming has been reported and very little has been looked for. Published animal studies describe no systemic toxicity. Practical reports from users centre on local injection-site reactions: erythema, transient swelling, mild pain. There is no long-term human safety monitoring, no data in pregnancy or paediatric use, and no interaction data with the biologic and disease-modifying drugs that osteoarthritis and inflammatory arthritis patients often take. A separate and underrated risk is supply: because Cartalax is not a regulated medicine anywhere, buyers depend on the sterility, identity and purity claims of grey-market vendors, and a certificate of analysis is the minimum sanity check before an injectable enters the body.

Our position: Cartalax is a mechanistically interesting molecule with a closed evidence loop. Until an independent laboratory reproduces the aggrecan and type II collagen findings, and until someone runs even a small placebo-controlled human trial with imaging or biomarker endpoints, it should be treated as an experimental compound rather than a joint therapy.